Ann: Break Through Animal Model Results, page-3

Good on them for making an announcement and nominating a day for shareholder meeting in July. From previous announcement

"We have approximately 40 second generation CPPs to test during Q2 before identifying a preferred ‘lead’ candidate/s. The lead candidates will be optimised for drug-like properties andundergo testing in larger animals (both efficacy and toxicity evaluation) before progressing to the clinic."

from current announcement we have only tested a small fraction. I thought we had hi throughput testing now so i guess the only frustration is why only a small fraction have been tested when this was our main focus for a quarter and much talk about our new scanning and testing capabilities. I wonder what a small fraction of 40 is? Again imyc fell by the wayside in the process of supposedly finding a "lead candidate" .


"We have achieved this result through testing of only a small fraction of our ‘second generation’ CPPs – we will now evaluate the remainder of these candidates inhuman retinal cells and animal models as we progress to selection of our leads for clinical development"

either way i like the fact they have enough respect for holders to ensure they followed up with an update in june. Nice change and for sure they are doing all yhey can.